[Skip to Navigation]
Sign In
Views 914
Citations 0
Comment & Response
June 17, 2021

Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?

Author Affiliations
  • 1Personalised Medicine Division, Walter and Eliza Hall Research Institute, Melbourne, Victoria, Australia
  • 2Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
JAMA Oncol. 2021;7(8):1246. doi:10.1001/jamaoncol.2021.1904

To the Editor Precision oncology offers thrilling therapeutic possibilities, as demonstrated by Cobain and colleagues1 in their cohort study. We do, however, have concerns regarding the generalizability of their findings, in particular, the expansive recommendation for “directed germline testing in all patients with advanced cancer.”1(p525)

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words